OLEMA PHARMACEUTICALS, INC. Deferred Tax Assets, Operating Loss Carryforwards
OLEMA PHARMACEUTICALS, INC. (OLMA) had Deferred Tax Assets, Operating Loss Carryforwards of $91.77 million as of 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsOperatingLossCarryforwards · last filed 2026-03-16
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards $91.77M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards $60.60M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards $44.70M.
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards $27.45M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards |
|---|---|
| 2025-12-31 | $91.77M 10-K · filed 2026-03-16 |
| 2024-12-31 | $60.60M 10-K · filed 2026-03-16 |
| 2023-12-31 | $44.70M 10-K · filed 2025-03-18 |
| 2022-12-31 | $27.45M 10-K · filed 2024-03-11 |
| 2021-12-31 | $17.89M 10-K · filed 2023-03-09 |
| 2020-12-31 | $6.17M 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |